FDA pursues shutdown recovery

Share this article:

Merck and Stallergenes are reclaiming their places in front of the FDA's advisory committees. The 16-day government shutdown scuttled the reviews of their allergy medications Grastek (Merck) and Oralair (Stallergenes), since they were not covered by the user fees that allowed the regulator to review and approve drugs while Congress froze government funding during the fight over healthcare reform.

The review committees are set for Dec. 12 (Merck) and Dec. 11 (Stallergenes).

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.